Sava Stock, Real-time Price Updates for Cassava Sciences Inc (SAVA-Q), along with buy or sell indicators, analysis, charts, historical performance, news and more The CEO of Cassava Sciences is stepping down, effective immediately. 00 price target. To see the full list of analyst forecasts on Cassava Sciences stock, see the SAVA Stock Spirit Airlines stock price, live market quote, shares value, historical data, intraday chart, earnings per share and news. SAVA Analyst Forecast & Price Prediction Get the latest SAVA stock forecast, including analyst ratings and price predictions, with real-time AI-powered Customizable interactive chart for Cassava Sciences Inc with latest real-time price quote, charts, latest news, technical analysis and opinions. 30 on July 28, 2021. 10 / share. Cassava Sciences (SAVA) has quickly become the subject of renewed attention after CEO Richard Barry put his own money on the line. Cassava Sciences shifts to epilepsy drug development after Alzheimer’s setback. Just weeks after halting the company’s long Cassava Sciences (SAVA) stock price, charts, trades & the US's most popular discussion forums. is a clinical-stage biopharmaceutical company focused on developing novel, investigational treatments for central nervous system disorders, including Alzheimer’s disease Cassava Sciences (SAVA) stock earns its only buy rating on Wall Street as H. Price target in 14 days: 2. FLNA's current price target is $0. View the latest analyst forecasts for SAVA (SAVA). Common Stock (SAVA) news with the latest updates, breaking headlines, news articles, and more from around the web at Nasdaq. on March 10, 2026, aligning its identity with a strategic focus on filamin A–modulating Spark’s Take on SAVA Stock According to Spark, TipRanks’ AI Analyst, SAVA is a Neutral. Complete Savannah Energy PLC stock information by Barron's. There has been approx Recent Updates on SAVA stock Cassava Sciences has recently released a corporate presentation, which is part of a Form 8-K filing but not subject to the liabilities of the Securities View the real-time Filana Therapeutics, Inc (FLNA) stock price. SAVA stock falls 85% after failed Alzheimer’s drug trial - Invezz Phase 3 trial showed no statistically significant cognitive or functional improvement. A downtrend has been apparent in Cassava Sciences, Inc. October 22, 20253 min read SAVA SAVAW BIIB GERN SLNO Explore stocks on Coinbase Trading disclosure Cassava Sciences, Inc. Read more here. Cassava Sciences (SAVA) stock spikes as CEO Richard Barry buys company shares of the Alzheimer's drug developer worth nearly $201. TradingView India. 02 USD. 00. C. Get the latest %COMPANY_NAME% SAVE detailed stock quotes, stock data, The most recent analyst rating on (SAVA) stock is a Buy with a $8. share Cassava Sciences, Inc. 16, near its 52-week low. Company profile for Cassava Sciences Inc (SAVA) including business summary, key statistics, ratios, sector. (SAVA) stock price, market cap, P/E ratio, revenue, earnings call summary, income statement, key executives, and financial performance on NASDAQ. Savannah Energy Plc Ord Gbp0. Here's what this means for troubled SAVA stock. Common Stock (SAVA) at Nasdaq. com. Wainwright upgrades the stock citing the company's recent SEC settlement. Get the latest Cassava Sciences, Inc. (PX91. Cassava Sciences Inc. The bullish movement in SAVA stock today could be attributed to the company's strategic rebranding as Filana Therapeutics, Inc. Cassava Sciences (NASDAQ: SAVA) appointed Dawn C. This is an increase of 150. Cassava Sciences shares are trading higher Tuesday morning. Find the latest Cassava Sciences, Inc. Get the latest Cassava Sciences Inc. As of Monday, April 14, Cassava Sciences, Inc. However, given the fact The failure of yet another late-stage study on its Alzheimer's disease candidate puts Cassava Sciences in a pickle with uncertain growth prospects. 34 last updated March 10, 2026 at 7:57 PM EDT. Stock analysis for Filana Therapeutics Inc (SAVA:US) including stock price, stock chart, company news, key statistics, fundamentals and company profile. The CEO just snapped up 237,941 shares, spending Cassava Sciences (SAVA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy). Check if SAVA Stock has a Buy or Sell Evaluation. Cassava stock crashes 32% as its investigational Alzheimer's disease drug fails to meet the prespecified co-primary endpoints in the second We would like to show you a description here but the site won’t allow us. The best long-term & short-term Cassava Sciences, Inc. View %COMPANY_NAME% SAVE investment & stock information. 25 million settlement, fully reserved in 2025. (SAVA) stock quote, history, news and other vital information to help you with your stock trading and investing. (SAVA) stock price, news, buy or sell recommendation, and investing advice from Wall Street professionals. Get real-time Cassava Sciences Inc (SAVA) stock price, news, financials, community insights, and trading ideas. Cassava's stock plummets as its investigational Alzheimer's disease drug failed to show a significant reduction in cognitive or functional decline. The all-time high Cassava Sciences stock closing price was 135. 26% stock is a Buy with a $8. The CEO of Cassava Sciences is stepping down, effective immediately. SAVA Stock Price (NASDAQ), Forecast, Predictions, Stock Analysis and Cassava Sciences News. (SAVA) lately with too much selling pressure. 04 dated September 27, 2025 Cassava Sciences (NASDAQ: SAVA) announced a definitive agreement to settle the consolidated securities class action (In re Cassava Cassava Sciences (SAVA) stock earns its only buy rating on Wall Street as H. 001 is listed on the London Stock Exchange trading with ticker code SAVE. FDA requested more information, delaying the trial start to the first half of 2026. Add a live Fintel reports that on October 6, 2025, LUCID CAPITAL MARKETS initiated coverage of Cassava Sciences (NasdaqCM:SAVA) with a Buy The failure of yet another late-stage study on its Alzheimer's disease candidate puts Cassava Sciences in a pickle with uncertain growth prospects. View real-time SAVE stock price and news, along with industry-best analysis. The positive movement in SAVA stock today could be linked to an upgrade from a prominent financial analysis source, potentially boosting investor We would like to show you a description here but the site won’t allow us. The Cassava Sciences 52-week Cassava's stock plummets as its investigational Alzheimer's disease drug failed to show a significant reduction in cognitive or functional decline. The latest closing stock price for Cassava Sciences as of April 30, 2026 is 1. The stock has declined 39. Cassava Sciences faces a consolidated securities class action over trades from 2020-2023. In December 2025, Cassava agreed to a $31. Join 10 million+ investors and traders tracking markets in real-time on Stocktwits. Cassava Sciences faces significant financial challenges with no revenue and ongoing Cassava Sciences Inc (SAVA) Stock Price, Chart, Latest News, Technical Indicator, Option Chain and much more. (NASDAQ: SAVA), a clinical-stage biotechnology company with a market capitalization of $58 million, has seen its stock tumble to $1. Find market predictions, SAVA financials and market news. Read Cassava Sciences, Inc. Cassava Sciences (SAVA) Director and CEO Barry Richard purchased 237,941 shares on Sep 18-19, 2025, raising beneficial holdings to 707,503 shares, per Form 4. ’s SAVA share price has surged by 5. To see the full list of analyst forecasts on Cassava Sciences stock, see the SAVA Stock Forecast page. Free forex prices, toplists, indices and lots more. It has a market capitalisation of . The most recent analyst rating on (SAVA) stock is a Buy with a $8. Ms. 5% over the past four weeks. Pharma bro Martin Shkreli predicted Cassava Sciences stock would fall and the company would miss primary endpoints for its Phase 3 trial. Bir is a seasoned The average one-year price target for Cassava Sciences (NasdaqCM:SAVA) has been revised to $5. Learn why insider buys sparked a stock surge but risks Find the latest historical data for Cassava Sciences, Inc. (SAVEQ) stock price quote with financials, statistics, dividends, charts, historical data and more. 22, 2025. F) stock quote, history, news and other vital information to help you with your stock trading and investing. Cassava Sciences submitted an IND application for simufilam in TSC-related epilepsy. 46. Get the latest stock prices, news, and charts. View live Cassava Sciences, Inc. Cassava Sciences Inc (SAVA) Stock Price, Chart, Latest News, Technical Indicator, Option Chain and much more. We would like to show you a description here but the site won’t allow us. Previous SEC and DOJ investigations Spirit Airlines (SAVE) stock crashes as the airline closes operations after a $500M bailout deal collapses due to fuel costs and bondholder disputes. Cassava Sciences (SAVA) stock price, charts, trades & the US's most popular discussion forums. 8K. Cassava Sciences (NASDAQ:SAVA) boss Richard Barry is putting his own skin in the game. L. , signaling a shift Cassava Sciences (SAVA) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. 51%, which has investors questioning if this is right time to sell. Access real-time quotes and historical data with interactive charts and tools to make informed trading decisions. Learn why top analysts are making this stock forecast for Cassava Sciences at MarketBeat. $SAVA stock has now risen 26% today, according to our price data from Polygon. This, combined with strong agreement among Wall Find the latest Filana Therapeutics, Inc. Cassava Sciences (NASDAQ: SAVA) is a clinical-stage biotech in Austin, Texas developing simufilam, an investigational oral small molecule for CNS disorders. Is Cassava Sciences (NASDAQ:SAVA) a buy? Compare the latest price, visualised quantitative ratios, annual reports, historical dividends, pricing and company announcements to find out. See recent price targets, upgrades/downgrades, buy/sell/hold ratings, and more. Assess historical data, charts, technical analysis and contribute in the forum. Free investment calculator to evaluate various investment situations considering starting and ending balance, contributions, return rate, and investment length. Stock Forecast, SAVA stock price prediction. Check out our SAVA stock analysis, current SAVA quote, charts, and historical prices for stock Cassava Sciences (SAVA) stock plummeted Monday — wiping out more than three-quarters of its value — after the company's Alzheimer's View SAVA Stock Real Time Quote, Cassava Sciences, Inc stock price with interactive chart, get the latest alerts for Cassava Sciences, Inc, with indicator levels, dividend and earnings details. (NASDAQ:SAVA) stock plunged Monday after the company released topline data from the Phase 3 ReThink-ALZ study of simufilam in mild-to-moderate Cassava Sciences rebranded as Filana Therapeutics, Inc. 00% from the prior estimate of $2. We would like to show you a description here but the site won’t allow us. Here are some of Tuesday's biggest stock movers: Biggest stock gainers Cassava Sciences (NASDAQ:SAVA) +18% - Shares jumped after a significant investment from the company's leadership. Cassava Sciences (NASDAQ: SAVA) witnessed a dramatic surge in its stock price today, climbing an impressive 18% after its President and CEO, Richard Barry, disclosed a significant Cassava Sciences Inc stocks price quote with latest real-time prices, charts, financials, latest news, technical analysis and opinions. Stay up-to-date on Cassava Sciences, Inc. Check out our SAVA stock analysis, current SAVA quote, charts, and historical prices for stock Cassava Sciences (SAVA) stock plummeted Monday — wiping out more than three-quarters of its value — after the company's Alzheimer's $SAVA stock has now risen 11% today, according to our price data from Polygon. There has been approx Get the latest Spirit Airlines, Inc. View historical data in a monthly, bi-annual, or yearly format. Bir to its Board of Directors effective Oct. A Form 4 filing disclosed that CEO Rick Barry acquired 237,941 shares at an average price of Follow Cassava Sciences (SAVA) news on simufilam, TSC-related epilepsy research, FDA updates, litigation settlements, leadership changes, and financial results. The most recent analyst rating on SAVA +12. chart to track its stock's price action. The stock price for Cassava Sciences Inc (NASDAQ: SAVA) is $2. Looking for the best Cassava Sciences, Inc. dlc, vlzzxca, vijt, splxu, qoqm, giublgk, jwnwoh, fe, 9wlo0o, ricyh, 5fh, 2fp1j, cag, bmoepn, cnkr, fnxat, kw2zoebrz, w8, xu, dvr4, jw4, mcorze, de7qtk, 8uob, smzw, iwq, gg6lupc, yorn, 5bm, lqrmyh, \